VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium, a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), today announced the successful completion of the first commercial procedures using its integrated mapping and ablation system, the Globe Pulsed Field System, following recent approval from the U.S. Food and Drug Administration (FDA). The […]
Rhythm
Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia
Study Results are Intended to Support PMA Approval of Adagio’s vCLASTM Cryoablation System Designed to Address the Large Population of Patients with Ventricular Arrhythmias LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today […]
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received notification from the United States Patent and Trademark Office of the allowance for issuance of two new patents.
Philips joins Optum Healthcare’s network as a preferred provider in the USA
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ Mobile Cardiac Telemetry (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of […]
Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management
KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients. “Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.” Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT
Bunkerhill Secures FDA Clearance for ECG-EF, Using AI to Detect Reduced Ejection Fraction from Routine ECGs
SAN FRANCISCO, Sept. 23, 2025 /PRNewswire/ — Bunkerhill Health today announced it has received U.S. Food and Drug Administration (FDA) clearance for ECG-EF, an artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF), a key indicator of heart…
eMyosound’s Revolutionary Echocardiography Technology to start Clinical Trial in Three Boston Hospitals
New generation of echocardiography modality for myocardial characterization: Real-time myocardial 3D Shear Wave Elastography Boston, September 8, 2025 – eMyosound – a French medical device company focused on assessing cardiac diseases through its groundbreaking ultrasound technology – has announced it is beginning a clinical trial in three major Boston hospitals. Led […]
Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus University Medical Center in Rotterdam, The Netherlands, using the advanced Genesis Robotic Magnetic Navigation System. “We have long recognized the clinical benefits of robotics, and are delighted to be the first in The Netherlands to make the Genesis robotic system available to cardiovascular patients,” said Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center. “We are impressed with the speed and responsiveness of Genesis. Combined with the MAGiC Catheter we are particularly pleased with the synergistic additive improvements to robotic magnetic navigation. These technological advances are important in ensuring we can offer the best care to all arrhythmia patients, including children, patients with congenital heart disease, and patients with complex arrhythmia.” Erasmus MC has been a global leader in using robotic magnetic navigation for complex arrhythmia procedures, having performed over 4,500 procedures with Stereotaxis technology. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. “We appreciate our long-term partnership with the electrophysiology team at Erasmus,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to continuing to support their successful robotic program and working together to advance technological progress, scientific discovery, and clinical care.” About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled. Stereotaxis Contacts: David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer 314-678-6100Investors@Stereotaxis.com
Argá Medtech Announces First Enrollments in COHERENT-AF IDE Clinical Trial
– Second generation pulsed field ablation system will be evaluated in paroxysmal and persistent atrial fibrillation patients to gain FDA approval – LAUSANNE, Switzerland and SAN DIEGO, Sept. 18, 2025 /PRNewswire/ — Argá Medtech, developers of the Coherent Sine-Burst Electroporation™…